WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

EU project IMMIDIET warns: control hypertension in Europe

Details
Research
13 November 2008
An EU-funded population study has shown that hypertension, an important risk factor for cardiovascular disease, is a serious problem in Europe. The results of the IMMIDIET project indicate that high blood pressure has become more common in Italy than in England or Belgium, a reversal of the commonly accepted trend.
Read more ...

New drug protects against diet-induced obesity and diabetes

Details
Research
06 November 2008
A recent EU-funded study by a Swiss-led international team of researchers has found that a new synthetic drug, developed by researchers in the US, protects against diet-induced obesity. At the same time, it improves glucose tolerance and insulin sensitivity and increases exercise endurance by enhancing fat utilisation in certain tissues.
Read more ...

Manhattan Research reports that the number of Health 2.0 consumers has doubled since 2007

Details
Research
04 November 2008
Manhattan ResearchOver 60 million U.S. adults are Health 2.0 consumers - reporting to use health blogs, online support groups, prescription rating sites, and other health-related social media applications, according to pharmaceutical and healthcare market research company Manhattan Research's just released Cybercitizen Health™ v8.0 consumer study and strategic advisory service.
Read more ...

New finding could lead to development of hundreds of new antibiotics

Details
Research
03 November 2008
EU-funded scientists have discovered a new molecule in Streptomyces bacteria that could be exploited to make the bacteria produce hundreds of novel antibiotics. The work, which is published online by the Proceedings of the National Academy of Sciences (PNAS), was partly supported by the EU-funded ACTINOGEN (Integrating genomics-based applications to exploit actinomycetes as a resource for new antibiotics) project.
Read more ...

Heinrich Wieland Prize: Closing in on the cause of diabetes

Details
Research
31 October 2008
Boehringer IngelheimFor his milestone discoveries on the development of diabetes, Prof. Markus Stoffel from the Institute of Molecular Systems Biology at the ETH Zurich was awarded the Heinrich Wieland Prize, one of the most treasured science awards in Germany. He received the distinction with EUR 50,000 prize money for his work in deciphering important mechanisms of blood sugar regulation and lipid metabolism in the body.
Read more ...

InforSense Collaborates with Industry Innovators to Enable Virtual Drug Discovery

Details
Research
30 October 2008
InforSense Ltd., the leading provider of next generation business and scientific intelligence tools, has successfully completed a pilot project at world leading pharmaceutical company GlaxoSmithKline (GSK) to enable virtual drug discovery through virtual outsourcing of data analysis via secure Grid technology.
Read more ...

Research agreement for the development of insulin-producing cells from human stem cells

Details
Research
23 October 2008
Novo NordiskNovo Nordisk A/S, a world leader in diabetes care, Cellartis AB, a forefront stem cell biotechnology company, and Lund University Stem Cell Center today signed a collaborative research agreement for the development of insulin-producing cells from human stem cells.
Read more ...

More Pharma News ...

  1. A new journal where molecular biology meets clinical research
  2. EMEA half-year report for 2008 shows activities to be on target
  3. New Media Offers Cost-Efficient Ways to Reach and Engage Targets
  4. Medicines regulators on both sides of the Atlantic confirm commitment to cooperation on medicines
  5. Philips develops ultrasound-activated microbubbles for localized delivery of cancer drugs
  6. Pharmaceutical Forum Concluded Successfully
  7. FDA Analysis on Cholesterol Lowering Medications
  • Start
  • Prev
  • 291
  • 292
  • 293
  • 294
  • 295
  • 296
  • 297
  • 298
  • 299
  • 300
  • Next
  • End
Tahmeena

Business & Industry

  • Pfizer reports record full-year 2022 results
  • AMJEVITA™ (adalimumab-atto), first biosimilar to Humira® now available in the United States
  • CHMP recommends Bayer’s darolutamide for the treatment of metastatic hormone-sensitive prostate cancer
  • Roche announces the European Commission approval of Xofluza for the treatment and prevention of influenza in children aged one year and above
  • Pfizer expands 'An Accord for a Healthier World' product offering to include full portfolio for greater benefit to 1.2 billion people in 45 lower-income countries

Research & Development

  • Scientists pinpoint protein that helps cancer-causing viruses evade immune response
  • Transforming the way cancer vaccines are designed and made
  • Antidepressants used for chronic pain on the rise, but are they effective?
  • Keys to making immunotherapy work against pancreatic cancer found in tumor microenvironment
  • Discovery of anti-cancer chemistry makes skullcap fit for modern medicine
  • Coordination of COVID-19 vaccine clinical trials produces a 'treasure trove' of data and a model for the future
  • Power of cancer drugs may see boost by targeting newly ID'd pathway

Conferences & Events

  • SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
  • SAE Media Group's 6th annual 3D Cell Culture Conference
  • CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
  • 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
  • CPHI Excellence in Pharma Award Winners 2022
  • CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
  • CPHI Frankfurt 2022: Global pharma confidence hits record high in the annual CPHI Pharma Index

Regulatory Affairs

  • FDA grants Accelerated Approval for Alzheimer's disease treatment
  • FDA approves new HIV drug for adults with limited treatment options
  • FDA approves first gene therapy for the treatment of high-risk, non-muscle-invasive bladder cancer
  • FDA approves first gene therapy to treat adults with Hemophilia B
  • FDA approves first treatment for Acid Sphingomyelinase Deficiency, a rare genetic disease
  1. You are here:  
  2. Home
  3. Research

About

  • Home
  • Advertise
  • Privacy
  • Cookie Preferences
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2023. All Rights Reserved.